Reuters logo
BioCryst's immune disorder drug succeeds in mid-stage trial
May 27, 2014 / 10:40 AM / 3 years ago

BioCryst's immune disorder drug succeeds in mid-stage trial

May 27 (Reuters) - BioCryst Pharmaceuticals Inc said its experimental drug for treating a rare immune disorder was effective in reducing the attacks of the disease in a mid-stage trial.

The drug, BCX4161, was compared with a placebo and was being tested in patients with hereditary angioedema (HAE) - a genetic disease characterized by sudden attacks of swelling of the skin or the mucous membranes, which can be disfiguring, painful and life-threatening.

Those treated with the drug had an average rate of 0.82 attacks per week, compared with 1.27 for those given a placebo. (Reporting by Esha Dey in Bangalore; Editing by Savio D‘Souza)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below